Feature Arbutus taking multi-faceted approach to HBV By Len Zehr Arbutus Biopharma (NASDAQ:ABUS) is developing a portfolio of drug candidates, each with different mechanisms of action that it believes will result in a combination therapy to cure patients infected with... January 17, 2017